SK Biopharmaceuticals Co Ltd

SK Biopharmaceuticals is a subsidiary of the SK Group, Korea's second largest corporation. Within the SK Group, it is in charge of developing innovative next-generation drugs. Many innovative drug candidates in the area of CNS have been developed by SK Biopharmaceuticals, led by the clinical development center (SK Life Science) in the United States and the research facility in Pangyo Techno-valley, Gyeonggi-do. The Company primarily develops and manufactures pharmaceuticals, such as epilepsy drugs, sleep disorder drugs, rare neurological disorder drugs, concentration disorder drugs, schizophrenia drugs, and bipolar disorder drugs. The company is also involved in the research of novel drugs.

SK Biopharmaceuticals is the only Korean business to have marketed two FDA-approved novel medications and to have developed cenobamate (an epileptic therapy) from discovery to FDA approval and commercialization. SK Biopharmaceuticals also discovered and licensed out solriamfetol (a therapy for sleep disorders), which received FDA and EMA approval. SK Biopharmaceuticals is expanding its research domain outside epilepsy, based on the gathered research capabilities. SK Biopharmaceuticals opened a research center in 2017 to begin its oncology expansion.

To become a true big biotechnology company, SK Biopharmaceuticals plans to diversify its product offerings beyond the treatment of central nervous system (CNS) disorders with drugs like anti-cancer treatment, cell and gene therapy (CGT), and digital therapeutics, building on successes like the successful commercialization of new drugs.

Founded: 1993
Headquarters: Gyeonggi, South Korea
Website: https://www.skbp.com/